Danimer Scientific — Q1 2023 Earnings Presentation
12 slides from Danimer Scientific's earnings presentation, May 10, 2023
Slide 1: First Quarter 2023 Earnings Presentation
First Quarter 2023 Earnings Presentation May 10, 2023
Slide 2: Disclaimer and Forward-Looking Statements
This presentation (“Presentation”) is for informational purposes only. This Presentation shall not constitute an offer to sell, or the solicitation of an offer to buy, any securities, nor shall there be any sale of securities in any states or jurisdictions in which such offer, solicitation or sale w
Slide 3: Fast Facts
FAST FACTS Founded in 2004 (went public in 2020) 480 patents & pending patent applications 15 partnerships with major brands and distributors 265 Teammates 2018 and 2020 recipient of PLASTICS Innovation in Bioplastics Award Locations in Georgia, Kentucky, and New York Manufacturer of PHA Biopolymers
Slide 4: Proprietary PHA-Based Resins with Disruptive Performance
Certified biodegradable for home compost, natural soil and marine environments Highly-engineered to run on standard manufacturing equipment Indistinguishable from petroleum plastic to consumers at end-use Proprietary PHA-Based Resins with Disruptive Performance 1 Switch to PHA-based resin requires s
Slide 5: Kentucky Manufacturing – Process & Capability
Kentucky Manufacturing – Process & Capability ¹ Intended to illustrate maximum potential at full utilization of design capacity; assumes pricing of $3 per lb. ~32.5 mm LBS of Neat PHA = ~65 mm LBS Formulated PHA-Based Resin = ~$190 mm Revenue¹ 5
Slide 6: Commercial and Operational Highlights
Began multi-store test of Nodax®-based straws with prominent QSR chain in preparation for wider roll-out in 2H23 In final discussions with customer requiring significant annual volumes of Nodax®-based straw resin, with first shipments expected in 2H23 In advanced negotiations with new customer requi
Slide 7: Q1 2023 Financial Summary
Q1 2023 Financial Summary Lower sales versus 1Q22 reflects a $2.1 million of net lower product shipments due to customer timing of PHA-based resins, partially offset by modest growth in PLA-based resin sales as well as $0.7 million of lower funded R&D revenue as customers move to commercialization.
Slide 8: Guidance Summary
1Q23 results in-line with expectations. Increased visibility and confidence in specific customer requirements. No adjustments to prior guidance. Customer timing adjustment now complete, expect return to quarterly YoY growth in 2Q23. Continue to expect acceleration of YoY revenue growth rates through
Slide 9: tess, ~ e
AN y . tess, ~ e Zé danimer \ oe soienutic. ‘y __ ABiotechnology Company
Slide 10: EBITDA Reconciliation
danimer EBITDA Reconciliation A Biotechnology Company Net loss $ (36,639) $ (26,386) Stock-based compensation 14,943 13,700 Depreciation and amortization 7579 4,259 Interest expense, net 3,386 992 Remeasurement of private warrants 1116 (4,995) Loss on extinguishment of royalty agreement 549 Loss on
Slide 11: Adjusted Gross Profit Reconciliation
Adjusted Gross Profit Reconciliation 10
Slide 12: Thank You
a danimer ~ scientific THANK YOU